How to Help Your Patients Find Spravato In Stock: A Provider's Guide

For psychiatrists, primary care physicians, and other prescribers who manage treatment-resistant depression (TRD), the clinical decision to prescribe Spravato is often straightforward. Getting the patient from prescription to treatment is not. The SPRAVATO REMS program, insurance hurdles, geographic access gaps, and cost barriers create a complex operational landscape that your practice must navigate on behalf of patients.

This guide provides step-by-step workflows your practice can use to maximize patient access to Spravato in 2026.

Step 1: Confirm REMS Certification for Your Setting (If Applicable)

If your practice intends to administer Spravato on-site, your healthcare setting must be certified in the SPRAVATO REMS program. This applies to all outpatient and inpatient settings. The process involves:

Completing the healthcare setting certification application at spravatorems.com

Designating staff responsible for patient monitoring during the 2-hour post-dose observation period

Ensuring your pharmacy supply chain is established through a REMS-certified specialty pharmacy

Training clinical staff on REMS requirements, post-dose monitoring protocols, and adverse event management

If your practice does not administer Spravato, your role is to prescribe and refer patients to a certified treatment center. You still need to be familiar with REMS requirements to counsel patients appropriately.

Step 2: Identify Certified Treatment Centers Near Your Patients

For patients who will be referred to an external certified center, use the SPRAVATO treatment center locator at spravato.com to identify nearby options. When counseling patients, prioritize centers that:

Accept the patient's specific insurance plan (verify before referral)

Are accessible by the patient's available transportation (remember: patients cannot drive themselves home)

Have available appointment slots within the patient's schedule constraints

Have an established relationship with your practice to facilitate warm handoffs

Step 3: Initiate Prior Authorization as Early as Possible

Prior authorization is required by virtually all commercial insurers, Medicare Advantage plans, and most Medicaid programs. Initiate the PA process the same day you make the prescribing decision — do not wait until after you've referred the patient to a treatment center. A proactive PA timeline is:

Day 0 (prescribing visit): Begin PA submission with complete documentation of TRD diagnosis and failed antidepressant trials

Day 1–7: Follow up with payer on PA submission status

Day 7–28: PA approval expected; schedule first treatment appointment upon approval

If denied: File appeal within 24–48 hours with peer-to-peer review request if available

Key documentation to have ready: PHQ-9 or MADRS scores, medication history with 2+ failed antidepressant trials (drug, dose, duration, reason stopped), DSM-5 diagnosis, confirmation of treatment at REMS-certified facility.

Step 4: Enroll Patients in the REMS Program

Outpatient patients must be enrolled in the SPRAVATO REMS program before their first treatment session. The treatment center often manages the patient enrollment paperwork, but as the prescriber you should confirm enrollment is complete before the patient's first appointment. Patient enrollment includes:

Signed patient acknowledgment form (understanding of risks including sedation, dissociation, need for monitoring)

Identification of a caregiver/driver who will transport the patient home after each session

Confirmation of administration in a REMS-certified outpatient setting

Step 5: Address Cost Barriers Proactively

For commercially insured patients, always refer them to the Spravato withMe Savings Program. Eligible patients can pay as little as $10 per treatment session for medication costs (up to $8,150 annual program benefit). This is a significant savings on a drug that costs hundreds of dollars per session without assistance.

For uninsured patients, the Spravato withMe Patient Assistance Program may provide medication at no or reduced cost for qualifying patients. Your practice coordinator or social worker should help patients apply for these programs before the first session.

Step 6: Counsel Patients on What to Expect

Setting accurate expectations increases treatment adherence and reduces dropout. Key counseling points include:

Dissociation is common (about 28% of TRD patients) and typically begins shortly after dosing; it usually resolves within 2 hours and tends to attenuate after repeated sessions

They should not eat for 2 hours or drink liquids for 30 minutes before each session

They will need a reliable caregiver or driver for every session — ride-share services alone may not be adequate if the patient is sedated or dissociating

Relief may begin within 24 hours of the first dose; full evaluation of response occurs at Day 28

Do not drive or operate heavy machinery until the next day after a restful sleep

medfinder for Providers: Supporting Your Patients' Full Medication Access

Your patients with TRD commonly take multiple other medications alongside or instead of Spravato. When those medications are hard to find at local pharmacies — a common situation with many psychiatric drugs — it disrupts their care. medfinder for providers is a service that calls pharmacies near your patients to find which ones have their prescriptions in stock — saving patients from the frustrating cycle of calling pharmacies themselves and reducing the risk of medication gaps.

For a broader clinical overview of the Spravato access situation, see: Spravato Shortage: What Providers and Prescribers Need to Know in 2026.